NFKB1 and lupus nephritis: An ongoing phase II trial in lupus nephritis patients is testing the nephroprotective effect of BIIB023 anti-TWEAK antibody.2 TWEAK is one of a handful of cytokines that activate the non-canonical NF-κB pathway and the only one to have been explored with respect to non-canonical NF-κB pathway activation in kidney cells.